Latest Breaking News On - Executive jeffrey eisenberg - Page 1 : comparemela.com

By Josh Beckerman Shares of cancer-focused Xenetic Biosciences were down 15% to $3.56 Wednesday following a presentation during the Virtual Investor Summer.

Curtisa lockshinJosh beckermanXenetic biosciencesJeffrey eisenbergVirtual investor summer spotlightExecutive jeffrey eisenbergChief scientific officer curtis